Clinical Trials Directory

Trials / Completed

CompletedNCT02525198

The Cognitive Ageing Nutrition and Neurogenesis (CANN) Trial

A Randomised Controlled Trial in 'At Risk' Humans Investigating the Cognitive Benefits of a Combined Flavonoid/Fatty Acid Intervention and Underlying Mechanisms of Action: The COGNITIVE AGING NUTRITION and NEUROGENESIS (CANN) Trial

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
259 (actual)
Sponsor
University of East Anglia · Academic / Other
Sex
All
Age
55 Years
Healthy volunteers
Accepted

Summary

There is a dearth of research which takes a multi-compound approach to dietary interventions, in humans, aimed at improving outcome measures of cognition. Animal research in particular points towards fatty acids and flavonoids having a potentiating effect on each other, and possibly even being synergistic. Thus, study products will be administered in the present trial comprising both of these compounds, with a view to investigating their potential effects on cognition in older adults with mild cognitive impairment (MCI) or subjective memory impairment (SMI).

Detailed description

240 participants, aged 55 or above, will be recruited (120 Norwich, 120 Melbourne; to include both MCI and SCI participants). Participants will be asked to take the study food each day for 12 months, and to come to the clinical assessment unit on 3 occasions, at baseline, 3 months and 12 months, to complete a cognitive task battery such that their performance may be investigated in the context of the intervention. Urine, blood and faecal samples will be collected and magnetic resonance imaging (MRI) will be applicable to half of each population (i.e to 60 MCI and 60 SCI, 30 of each at Norwich and Melbourne).

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTfatty acid/flavonoid blendsee arm description
DIETARY_SUPPLEMENTPlacebosee arm description

Timeline

Start date
2015-08-01
Primary completion
2018-03-31
Completion
2018-03-31
First posted
2015-08-17
Last updated
2024-05-14

Locations

3 sites across 3 countries: United States, Australia, United Kingdom

Source: ClinicalTrials.gov record NCT02525198. Inclusion in this directory is not an endorsement.